PharmaCyte Biotech invests $5M in Femasys, expanding strategy to utilize $74.6M cash

PharmaCyte Biotech, Inc.

PharmaCyte (PMCB) purchases $5M senior unsecured convertible notes from Femasys (FEMY) at 6% interest, maturing in 2 years.
Notes convertible at $1.18/share; warrants to buy up to ~8.5M FEMY shares at $1.18 and $1.475 per share.
Interim CEO Josh Silverman will join Femasys' Board of Directors; collaboration agreement for joint research.
PharmaCyte had $74.6M cash as of July 31, 2023; investment marks first external tech deployment.
Femasys offers women's health products including late-stage FemBloc and FDA-cleared FemaSeed.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PharmaCyte Biotech, Inc. entered into Collaboration Agreement with Femasys Inc. (effective 2023-11-14).

Action: entry
Agreement: collaboration
Counterparty: Femasys Inc.
Effective: 2023-11-14

Exact text from the filing

ith Femasys Inc. (“Femasys”) , pursuant to which it agreed to purchase from Femasys (i) senior unsecured convertible notes (the “Notes”) in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PharmaCyte Biotech, Inc. entered into Registration Rights Agreement with Femasys Inc..

Action: entry
Counterparty: Femasys Inc.

Exact text from the filing

ith Femasys Inc. (“Femasys”) , pursuant to which it agreed to purchase from Femasys (i) senior unsecured convertible notes (the “Notes”) in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PharmaCyte Biotech, Inc. entered into Purchase Agreement with Femasys Inc. valued at $5,000,000 (effective 2023-11-14).

Action: entry
Agreement: equity purchase
Counterparty: Femasys Inc.
Value: $5,000,000
Effective: 2023-11-14

Exact text from the filing

On November 14, 2023, PharmaCyte Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Femasys Inc. (“Femasys”)

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

PharmaCyte Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-008204

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.